<span item_type="fundamental" item_id="b968bfbea923a9db5873abccccab06b2" counter_id="ST/US/RPID" env="prod"></span><span item_type="announcement" item_id="648018422836174465" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 8.002 M, beating the estimate of USD 7.6 M.</p><p>EPS: As of FY2026 Q1, the actual value is USD -0.31, missing the estimate of USD -0.2467.</p><p>EBIT: As of FY2026 Q1, the actual value is USD -13.47 M.</p><p></p><h4>Revenue</h4><p>Total revenue for Rapid Micro Biosystems, Inc. increased by 11.1% to $8.0 million in the first quarter of 2026, up from $7.2 million in the first quarter of 2025, specifically $8,002 thousand in Q1 2026 compared to $7,205 thousand in Q1 2025. Product revenue increased by 36.0% to $5.6 million in Q1 2026, from $4.1 million in Q1 2025, amounting to $5,578 thousand in Q1 2026 compared to $4,101 thousand in Q1 2025. Service revenue declined by 21.9% to $2.4 million in Q1 2026, from $3.1 million in Q1 2025, primarily due to lower validation activity, with figures of $2,424 thousand in Q1 2026 compared to $3,104 thousand in Q1 2025. Recurring revenue increased by 27.7% to $5.1 million in Q1 2026, compared to $4.0 million in Q1 2025, and comprised 63% of total revenue in Q1 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1380106/000138010626000067/rpid-20260331xexx991.htm"></span></p><h4>Cost of Revenue and Gross Margin</h4><p>Total cost of revenue increased by 12.2% to $7.6 million in Q1 2026, from $6.8 million in Q1 2025, specifically $7,631 thousand in Q1 2026 compared to $6,801 thousand in Q1 2025. Cost of product revenue was $6,025 thousand in Q1 2026, compared to $5,029 thousand in Q1 2025. Cost of service revenue was $1,606 thousand in Q1 2026, compared to $1,772 thousand in Q1 2025. Gross margin for Q1 2026 was $0.4 million, or 4.6%, compared to $0.4 million, or 5.6%, in Q1 2025, with specific figures of $371 thousand in Q1 2026 compared to $404 thousand in Q1 2025. Product gross margin percentage increased by 15-percentage points, and consumable gross margin increased by 33-percentage points in Q1 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1380106/000138010626000067/rpid-20260331xexx991.htm"></span></p><h4>Operating Expenses</h4><p>Total operating expenses increased by 17.9% to $14.2 million in Q1 2026, compared to $12.1 million in Q1 2025, amounting to $14,223 thousand in Q1 2026 compared to $12,065 thousand in Q1 2025. Research and development expenses decreased by 7.3%, amounting to $3,359 thousand in Q1 2026, down from $3,624 thousand in Q1 2025. Sales and marketing expenses increased by 24.4%, amounting to $3,422 thousand in Q1 2026, up from $2,751 thousand in Q1 2025. General and administrative expenses increased by 30.8%, amounting to $7,442 thousand in Q1 2026, up from $5,690 thousand in Q1 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1380106/000138010626000067/rpid-20260331xexx991.htm"></span></p><h4>Operational Metrics</h4><p>Rapid Micro Biosystems, Inc. placed 6 Growth Direct systems in Q1 2026, compared to 3 systems in Q1 2025. The company completed the validation of 5 customer systems in Q1 2026, compared to 9 validations in Q1 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1380106/000138010626000067/rpid-20260331xexx991.htm"></span></p><h4>Net Loss</h4><p>Loss from operations was - $13,852 thousand in Q1 2026, compared to - $11,661 thousand in Q1 2025. Net loss for Q1 2026 was - $14.3 million, compared to a net loss of - $11.3 million in Q1 2025, specifically - $14,275 thousand in Q1 2026 compared to - $11,263 thousand in Q1 2025. Net loss per share was - $0.31 in Q1 2026, compared to - $0.26 in Q1 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1380106/000138010626000067/rpid-20260331xexx991.htm"></span></p><h4>Cash and Investments</h4><p>Cash, cash equivalents, short-term investments, and restricted cash were approximately $23 million as of March 31, 2026, compared to $38,580 thousand as of December 31, 2025. Cash and cash equivalents were $13,815 thousand as of March 31, 2026, compared to $20,030 thousand as of December 31, 2025. Short-term investments were $9,134 thousand as of March 31, 2026, compared to $18,266 thousand as of December 31, 2025. Restricted cash was $284 thousand as of March 31, 2026, and December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1380106/000138010626000067/rpid-20260331xexx991.htm"></span></p><h4>Full Year 2026 Outlook</h4><p>Rapid Micro Biosystems, Inc. reaffirms its full year 2026 total revenue guidance range of $37.0 million to $41.0 million. This guidance includes 30 to 38 Growth Direct system placements and at least 25 system validations. The company also projects a full year 2026 gross margin percentage of approximately 20%, with a Q4 2026 exit rate in the mid-20% range.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1380106/000138010626000067/rpid-20260331xexx991.htm"></span></p>

Rapid Micro Biosystems | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 8.002 M